Clinical meaning
Systematic lipid monitoring is essential for assessing treatment response, guiding therapy adjustments, and ensuring long-term ASCVD risk reduction. The timing, frequency, and interpretation of lipid panels in the context of ongoing therapy requires nuanced clinical judgment.
Baseline fasting lipid panel should be obtained before initiating statin therapy. Follow-up fasting lipid panel should be checked 4-12 weeks after starting or adjusting statin therapy. This interval allows time for the statin to reach steady-state and for LDL receptor upregulation to achieve maximal effect. Expected LDL reduction varies by statin intensity: high-intensity (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) should reduce LDL by >=50%; moderate-intensity should reduce LDL by 30-49%.
If the expected LDL reduction is not achieved, the NP should: (1) assess adherence (most common cause), (2) reinforce administration instructions, (3) evaluate for drug interactions (CYP3A4 inducers can reduce statin levels), (4) assess dietary factors, and (5) consider adding ezetimibe or increasing statin dose.
Once LDL goal is achieved and stable, monitoring frequency decreases to annually. Secondary causes of dyslipidemia must be excluded: hypothyroidism (increases LDL), nephrotic syndrome (increases total cholesterol), obstructive liver disease (increases cholesterol), diabetes (increases triglycerides, reduces HDL), and medications (corticosteroids, protease inhibitors, thiazides, beta-blockers).